Find News

Filter articles

Showing 3921 to 3930 of 4007 results

Myriad patent suit enters antitrust territory


Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.

Indian patent office strikes down another blockbuster patent


The Kolkata Patent Office has refused divisional patents related to Swiss pharmaceutical company Roche’s breast cancer drug Herceptin.

Eversheds secures former Sidley Austin IP and life sciences head


Eversheds has appointed the former head of Sidley Austin's London IP and life sciences team Brett Rowland, as a partner.

Roche signs drug licensing agreement with MPP


On August 5, Swiss pharmaceutical company Roche signed an agreement with the MPP to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).

Section 3(d) strikes again in GSK India patent defeat


India’s Intellectual Property Appeal Board has revoked a patent covering GlaxoSmithKline’s breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.

IPAB throws out Indian Vega trademarks


The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.

UK Appeals Court upholds Teva’s Copaxone patent

UK01-08-2013Legal developments

The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

US court rules Teva patent invalid


A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

Novozymes loses appeal in DuPont patent war


A US court has upheld a decision ruling that a continuation patent filed by a bio-tech company is invalid.

FTC welcomes Supreme Court 'pay-for-delay' ruling


The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.

Showing 3921 to 3930 of 4007 results